Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:4:261-8.
doi: 10.2147/CEOR.S35046. Epub 2012 Sep 13.

Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation

Giorgio L Colombo  1 , Sergio Di Matteo, Giacomo Bruno, Giampiero Girolomoni, Gino Antonio Vena
Affiliations

Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation

Giorgio L Colombo et al. Clinicoecon Outcomes Res. 2012.

Abstract

Background: Psoriasis is a chronic inflammatory skin disease with a major impact on the quality of life of affected individuals. Topical therapy has an important role in the treatment of psoriasis. Poor treatment outcomes from topical therapy regimens likely result from poor adherence and ineffective use of medication.

Methods: A cost-minimization analysis was performed with the purpose of assessing the use of a gel containing calcipotriol and betamethasone dipropionate (Dovobet(®) gel) versus the ointment formulation (Dovobet ointment) in the treatment of psoriasis. The analysis was carried out using a Markov model with a one-year time horizon in a hypothetical cohort of patients with a Psoriasis Area and Severity Index score < 10. The model simulates different therapy adherence scenarios for the two different formulations.

Results: The Dovobet gel strategy allows a 5% reduction in the number of patients who could potentially be treated with more expensive therapies (biologics and conventional systemic drugs) in comparison with the Dovobet ointment strategy, with a consequent impact on costs for the National Healthcare Service. The total annual cost of Dovobet gel is about €407.00 per patient, ie, 19% less that the total cost of about €500.00 of the Dovobet ointment strategy. The base case results were then examined by sensitivity analysis and budget impact analysis to correlate the various scenarios of Dovobet gel use with cost savings to the National Healthcare Service.

Conclusion: The Dovobet gel strategy seems more acceptable to patients, shows better overall adherence, and appears to be favorable from the pharmacoeconomic point of view than the ointment formulation for treatment of patients with mild-to-moderate psoriasis.

Keywords: calcipotriol and betamethasone dipropionate; cost-consequences; cost-minimization; patient adherence; pharmacoeconomics; psoriasis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of the model: pathway of the patient not responding to topical treatment.
Figure 2
Figure 2
Percentage distribution of patients by treatment.
Figure 3
Figure 3
Total annual average costs (€) per patient by treatment.
See this image and copyright information in PMC

References

    1. Plunkett A, Marks R. A review of the epidemiology of psoriasis vulgaris in the community. Australas J Dermatol. 1995;39:225–232. - PubMed
    1. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151( Suppl 69):3–17. - PubMed
    1. Naldi L, Colombo P, Benedetti Placchesi E, et al. Study design and preliminary results from the pilot phase of the Praktis study: self reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology. 2004;208:38–42. - PubMed
    1. Finlay AY. Current severe psoriasis and the Rule of Tens. Br J Dermatol. 2005;152:861–867. - PubMed
    1. Kirby B, Fortune DG, Bhushan M, et al. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol. 2000;142:728–732. - PubMed